Limertinib

DRUG4 trials

Sponsors

Shanghai Chest Hospital, Hunan Province Tumor Hospital, Innovent Biologics (Suzhou) Co. Ltd., Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Conditions

EGFR Activating MutationEGFR Mutation Positive Advanced Non Small Cell Lung CancerMET PositiveNon Small Cell Lung CancerNon Small Cell Lung Cancer NSCLCNon-Squamous Non-Small Cell Lung Cancer (NSCLC)PD-L1 PositiveSmall Cell Lung Cancer

Phase 1

Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

Not yet recruitingNCT07612137

Innovent Biologics (Suzhou) Co. Ltd.Solid Tumor

Start: 2026-06-01End: 2028-06-30Target: 282Updated: 2026-05-28

Phase 2

A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.

Not yet recruitingNCT06982924

Shanghai Chest HospitalEGFR Mutation Positive Advanced Non Small Cell Lung Cancer, PD-L1 Positive

Start: 2025-06-30End: 2028-12-30Target: 136Updated: 2025-05-21

Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression

Not yet recruitingNCT07001995

Hunan Province Tumor HospitalNon Small Cell Lung Cancer, Non Small Cell Lung Cancer NSCLC, Small Cell Lung Cancer

Start: 2026-05-01End: 2028-12-30Target: 30Updated: 2026-03-16

Phase 3

ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC

Not yet recruitingNCT07897188

Jiangsu Aosaikang Pharmaceutical Co., Ltd.EGFR Activating Mutation, MET Positive, Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Start: 2026-10-30End: 2032-11-20Target: 425Updated: 2026-10-27